One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Adaptive Biotechnologies Corp before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Adaptive Biotechnologies Corp’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Adaptive Biotechnologies Corp’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Adaptive Biotechnologies Corp (ADPT)

Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Want to learn more about Adaptive Biotechnologies Corp’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Adaptive Biotechnologies Corp. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Adaptive Biotechnologies Corp’s Stock Price as of Market Close

As of September 18, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $5.52.

Adaptive Biotechnologies Corp is down 8.91% from its previous closing price of $6.06.

During the last market session, Adaptive Biotechnologies Corp’s stock traded between $6.05 and $6.28. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase.

Unfortunately, Adaptive Biotechnologies Corp’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Adaptive Biotechnologies Corp Stock Price History

Adaptive Biotechnologies Corp’s (ADPT) price is currently down 18.46% so far this month.

During the month of September, Adaptive Biotechnologies Corp’s stock price has reached a high of $6.96 and a low of $5.51.

Over the last year, Adaptive Biotechnologies Corp has hit prices as high as $10.79 and as low as $5.96. Year to date, Adaptive Biotechnologies Corp’s stock is down 80.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Adaptive Biotechnologies Corp Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 15, 2023, there were 9 analysts who downgraded Adaptive Biotechnologies Corp’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Adaptive Biotechnologies Corp’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Adaptive Biotechnologies Corp’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Adaptive Biotechnologies Corp (ADPT) by visiting AAII Stock Evaluator.

Relative Price Strength of Adaptive Biotechnologies Corp

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of September 15, 2023, Adaptive Biotechnologies Corp has a weighted four-quarter relative price strength of -13.89%, which translates to a Momentum Score of 26 and is considered to be Weak.

Want to learn more about how Adaptive Biotechnologies Corp is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Adaptive Biotechnologies Corp Stock Price: Bottom Line

As of September 18, 2023, Adaptive Biotechnologies Corp’s stock price is $5.52, which is down 8.91% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Adaptive Biotechnologies Corp’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.